Is seputinib/serpatinib a targeted drug?

Selpercatinib/Selpercatinib is a targeted drug targeting RET gene mutations. It is a small molecule receptor tyrosine kinase inhibitor with high selectivity and inhibitory activity. It can inhibit a variety of receptor tyrosine kinase mutations and mainly treats malignant tumors with RET gene mutations or rearrangements, such as non-small cell lung cancer, medullary thyroid cancer, thyroid cancer, etc. Compared with other targeted drugs, seputinib has stronger selectivity and affinity, can act on multiple targets at the same time, effectively inhibits the spread of cancer cells, makes the treatment more effective, and the patient's survival period is relatively longer. Patients need to follow the doctor's instructions and pay attention to the use of drugs and side effects management to ensure treatment effectiveness and safety.